ctDNA-guided therapy after stomach cancer treatment
Part of Cancer, Digestive system clinical trials.
This trial tests whether using a blood test for cancer DNA (ctDNA) can help decide if more chemotherapy is needed after surgery and chemo for advanced stomach cancer. It may help tailor treatment to your individual risk of cancer returning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with stomach or gastroesophageal junction cancer that is locally advanced (stage cIIB-IVA) and can be removed by surgery.
- You have not had any cancer treatment yet for this current cancer.
- You are healthy enough for surgery and have a good performance status (ECOG 0-2).
- Your blood counts and organ function (kidney, liver, clotting) meet specific lab criteria before starting neoadjuvant chemo.
- You agree to use effective contraception if you could become pregnant or father a child during the study and for 24 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using a blood test for tumor DNA (ctDNA) can help decide who needs more chemotherapy after surgery for advanced stomach cancer. The goal is to personalize treatment and avoid unnecessary side effects.
This trial tests a new therapy called CT0494BCP for advanced stomach cancer (including cancers at the junction between the esophagus and stomach) that hasn't responded to at least two prior treatments. The therapy is designed to target a specific protein called CLDN18.2 found on your cancer cells, combined with immune-boosting treatment.
This study uses special blood tests to detect cancer DNA and help doctors decide the best treatment plan for gastric cancer. The goal is to improve outcomes by personalizing therapy based on how your cancer responds.
This trial checks whether a blood test after surgery (ctDNA) can help decide if you should receive additional “adjuvant” treatment for stomach, gastroesophageal junction, or lower esophagus cancer that has HER2-positive tumors. It may help reduce the chance of cancer coming back by tailoring therapy to your risk based on the ctDNA result.
This study tests whether personalized adjuvant therapy, guided by ctDNA levels in your blood, can reduce the risk of cancer returning after surgery for stage III or IVA stomach or gastroesophageal junction cancer. It is for individuals with HER2-negative disease who are candidates for surgery and have not had prior treatment.
This study tests whether a simple blood test (called ctDNA) can help decide if you need additional chemotherapy after surgery for stomach or esophageal cancer. The goal is to avoid unnecessary treatment for patients who are already cancer-free while ensuring those who need it get the right therapy.
Hear when a new Gastric / Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.